Autolus Therapeutics plc Retained Earnings
Autolus Therapeutics plc (AUTL) had Retained Earnings of -$1.50 billion as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Balance Sheet › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-11
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$1.50B.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$1.46B.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$1.39B.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$1.30B.
| Period end | Retained Earnings (Accumulated Deficit) |
|---|---|
| 2026-06-30 | -$1.50B 10-Q · filed 2026-08-11 |
| 2026-03-31 | -$1.46B 10-Q · filed 2026-05-14 |
| 2025-12-31 | -$1.39B 10-Q · filed 2026-08-11 |
| 2025-09-30 | -$1.30B 10-Q · filed 2025-11-12 |
| 2025-06-30 | -$1.22B 10-Q · filed 2025-08-12 |
| 2025-03-31 | -$1.17B 10-Q · filed 2025-05-08 |
| 2024-12-31 | -$1.10B 10-K · filed 2026-03-27 |
| 2024-09-30 | -$1.07B 10-Q · filed 2024-11-12 |
| 2024-06-30 | -$989.52M 10-Q · filed 2024-08-08 |
| 2024-03-31 | -$931.25M 10-Q · filed 2024-05-17 |
| 2023-12-31 | -$878.56M 10-K · filed 2025-03-20 |
| 2023-09-30 | -$801.39M 10-K · filed 2024-03-21 |
| 2023-06-30 | -$755.54M 10-K · filed 2024-03-21 |
| 2023-03-31 | -$709.99M 10-K · filed 2024-03-21 |
| 2022-12-31 | -$670.18M 10-K · filed 2024-03-21 |
| 2022-09-30 | -$643.23M 10-K · filed 2024-03-21 |
| 2022-06-30 | -$600.46M 10-K · filed 2024-03-21 |
| 2022-03-31 | -$558.40M 10-K · filed 2024-03-21 |
| 2021-12-31 | -$521.34M 20-F · filed 2023-03-07 |
| 2021-03-31 | -$412.51M 6-K · filed 2021-05-06 |
| 2020-12-31 | -$379.24M 20-F · filed 2022-03-10 |
| 2020-09-30 | -$336.38M 6-K · filed 2020-11-05 |
| 2020-06-30 | -$299.07M 6-K · filed 2020-08-06 |
| 2020-03-31 | -$267.02M 6-K · filed 2020-05-07 |
| 2019-12-31 | -$237.15M 20-F · filed 2021-03-04 |
| 2019-09-30 | -$196.21M 6-K · filed 2019-11-07 |
| 2019-06-30 | -$168.96M 6-K · filed 2019-08-08 |
| 2018-12-31 | -$113.30M 20-F · filed 2020-03-03 |
| 2018-09-30 | -$92.65M 20-F · filed 2019-02-25 |
| 2017-09-30 | -$47.90M 20-F · filed 2019-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 |